If you have been reading about deamidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Two adults and five children at the Kindercare kindergarten in Christchurch suffer chemical burns after being accidentally exposed to a hazardous substance being poured on a waterslide. The Controller and Auditor-General of New Zealand launches an investigation into the Chatham Islands Council's expenditure and procurement policies. Craig Stobo temporarily steps down as chairperson of the Financial Market Authority pending an investigation by the Ministry of Business, Innovation and Employment (MBIE). 6 December — A measles case is reported in Queenstown, bringing the total number of cases reported nationally to 30. 22 cases are no longer infectious. 8 December: A wildfire engulfs over 320 hectares of Tongariro National Park, leading to the closure of sections of State Highway 47. Significant firefighting resources including 60 firefighters, 16 vehicles and nine helicopters are deployed to contain the blaze. The National Iwi Chairs Forum delivers a 24,000-strong petition urging the Education Minister Erica Stanford to reverse an amendment abolishing the requirement for school boards to uphold the Treaty of Waitangi. 9 December: The Supreme Court of New Zealand rules that two parents who care for their severely disabled adult children should be recognised as homeworkers who are entitled to the minimum wage. The New Zealand Government announces two proposed bills to replace the Resource Management Act 1991.
Chiral column chromatography is a variant of column chromatography that is employed for the separation of chiral compounds, i.e. enantiomers, in mixtures such as racemates or related compounds. The chiral stationary phase (CSP) is made of a support, usually silica based, on which a chiral reagent or a macromolecule with numerous chiral centers is bonded or immobilized. The chiral stationary phase can be prepared by attaching a chiral compound to the surface of an achiral support such as silica gel. For example, one class of the most commonly used chiral stationary phases both in liquid chromatography and supercritical fluid chromatography is based on oligosaccharides such as amylose, cellulose, or cyclodextrin (in particular with β-cyclodextrin, a seven sugar ring molecule) immobilized on silica gel. The principle can be also applied to the fabrication of Monolithic HPLC columns or Gas Chromatography columns. or Supercritical Fluid Chromatography columns.
During examinations of the head and torso, this scattered radiation can spread throughout the body and is difficult to shield with radiation protective clothing. Fears that a lead apron will prevent radiation from leaving the body are unfounded, however, because lead absorbs radiation rather than scattering it. When preparing an orthopantomogram (OPG) for a dental overview radiograph, it is sometimes recommended not to wear a lead apron, as it does little to shield scattered radiation from the jaw area, but may hinder the rotation of the imaging device. However, according to the 2018 X-ray regulation, it is still mandatory to wear a lead apron when taking an OPG.
Nipple pain is a common symptom of pain at the nipple that occurs in women during breastfeeding after childbirth. The pain shows the highest intensity during the third to the seventh day postpartum and becomes most severe on the third day postpartum. Nipple pain can result from many conditions. Early nipple pain in breastfeeding is usually caused by improper positioning and latch while breastfeeding. Other causes may include blocked milk ducts, tongue-tie, cracked nipples and nipple infections by yeasts, bacteria or viruses. Complications in nursing women involve an increase in nipple sensitivity or breast engorgement, leading to mastitis and subsequent pain. Common diagnostic approaches include quantifying pain by the numerical rating scale (NRS) and maternal breast or infant mouth examinations. Nipple pain may hinder breastfeeding and is the most common reason for early weaning. General management such as positioning and latch adjustment and thermal intervention can be administered for pain alleviation. Appropriate treatment of nipple pain is given based on the underlying cause.
==== Banking reform ==== In 1999, Sanders voted and advocated against rolling back the Glass–Steagall legislation provisions that kept investment banks and commercial banks separate entities. He was a vocal critic of Federal Reserve chair Alan Greenspan; in June 2003, during a question-and-answer discussion, Sanders told him he was concerned that he was "way out of touch" and "that you see your major function in your position as the need to represent the wealthy and large corporations."
Sources: en.wikipedia.org
=== Alexander Norton === Viscount Alexander Norton (Andrew Havill) is Henry Muck’s uncle and a powerful newspaper proprietor who owns several British tabloids. A wealthy aristocrat with a large country estate, he is a former Oxford classmate of Charles Hanani and a close ally of Otto Mostyn. In series 3, Norton works with Otto and Conservative MP Aurore Adekunle to exploit the collapse of Lumi and the failed Barclays acquisition of Pierpoint for political advantage. As Yasmin faces mounting negative press following her father’s embezzlement scandal and death, Norton offers to suppress damaging coverage and urges her to marry Henry, assuring her of his family’s protection and financial security. He also tells Yasmin he had long known of Charles’s predatory behavior and that she bears no responsibility. In series 4, Norton remains involved in Henry’s life after his brief parliamentary career ends. Aware that Henry’s father died by suicide on his 40th birthday, Norton unsuccessfully tries to lift him from a depressive spiral during the same milestone. He meets with Labour MP Jennifer Bevan, Henry’s successor, who confronts him about his alarmist headlines about the economy, which she fears could contribute to a recession. Norton tells her that her superior, far-left business secretary Lisa Dearn, is "anti-business". After Henry becomes CEO of fintech company Tender, Yasmin enlists Norton to run headlines smearing financial journalist James Dycker (who is investigating Tender) as colluding with short sellers, which helps contribute to Dycker's firing.
CB03-154 is a Kv7.2 and Kv7.3 potassium channel opener which is under development for the treatment of amyotrophic lateral sclerosis (ALS), epilepsy, major depressive disorder, bipolar disorders, stroke, and pain in China. It is taken orally. The drug is said to have higher selectivity and stability compared to retigabine. CB03-154 is under development by Shanghai Zhimeng Biopharma. As of November 2025, it is in 2/3 clinical trials for ALS, phase 2 trials for epilepsy and major depressive disorder, phase 1 trials for bipolar disorders, and the preclinical research stage of development for stroke, whereas no recent development has been reported for pain.
Only a year after Röntgen's discovery of X-rays, the American engineer Wolfram Fuchs (1896) gave what is probably the first protection advice, but it was not until 1925 that the first International Congress of Radiology (ICR) was held and considered establishing international protection standards. The effects of radiation on genes, including the effect of cancer risk, were recognized much later. In 1927, Hermann Joseph Muller published research showing genetic effects and, in 1946, was awarded the Nobel Prize in Physiology or Medicine for his findings. The second ICR was held in Stockholm in 1928 and proposed the adoption of the röntgen unit, and the International X-ray and Radium Protection Committee (IXRPC) was formed. Rolf Sievert was named chairman, but a driving force was George Kaye of the British National Physical Laboratory. The committee met in 1931, 1934, and 1937. After World War II, the increased range and quantity of radioactive substances being handled as a result of military and civil nuclear programs led to large groups of occupational workers and the public being potentially exposed to harmful levels of ionising radiation. This was considered at the first post-war ICR convened in London in 1950, when the present International Commission on Radiological Protection (ICRP) was born. Since then the ICRP has developed the present international system of radiation protection, covering all aspects of radiation hazards.
Peukert wrote that the popular claim, made after the war, that the Nazi regime stayed in power only because of terror was incorrect. Peukert wrote though terror played a role in sustaining the Nazi regime, the majority of victims of the violence of that the German state inflicted in the Nazi era tended to be people considered to be "outsiders" in Germany like Jews, the Romany, "Marxists", the mentally ill, the disabled, homosexuals, Jehovah's Witnesses, and the "asocial", and that for the most part, the state in the Nazi era left ordinary Germans alone to live their lives as they pleased. Peukert wrote with the "popular experience" of most Germans in the Nazi era, there were no clear-cut "villains and victims" with the American historian David Crew writing that Peukert had presented "a complex, morally disturbing picture" of ordinary people adjusting to what Peukert called "the multiple ambiguities of ordinary people". Peukert wrote that most ordinary Germans lived in a "grey zone" choosing support, accommodation and nonconformity at various times, never totally supporting the Nazi regime, but willing to accommodate themselves to the regime provided it served their own self-interests.
Sources: en.wikipedia.org
Shulman proposed that lipid-induced insulin resistance results from the accumulation of sn-1,2-diacylglycerol (DAG) in the plasma membrane, which activates novel protein kinase C (nPKC) isoforms—PKCθ in skeletal muscle and PKCε in liver and white adipose tissue—impairing insulin signaling. Shulman's lab explored interventions such as weight loss, thiazolidinediones, adiponectin, leptin, and liver-targeted mitochondrial protonophores to reverse insulin resistance by lowering plasma membrane DAG and inhibiting the nPKC pathway. He also pioneered 13C and 31P NMR methods to measure ATP synthesis and mitochondrial oxidation in vivo. His team identified age-related declines in mitochondrial fat oxidation linked to insulin resistance in elderly individuals, and in insulin-resistant offspring of people with T2D. They showed that chronic AMPK activation drives mitochondrial biogenesis via increased expression of PGC-1α. Shulman used 13C NMR to quantify rates of hepatic glycogenolysis and gluconeogenesis, showing that the latter accounts for over half of fasting hepatic glucose production following an overnight fast overturning the Cahill hypothesis that hepatic glycogenolysis accounts for >90% of glucose production in humans following an overnight fast.
There are ten official universities in Israel, of which nine are public, a few dozen colleges, and about a dozen foreign university extensions. The Council for Higher Education in Israel supervises all of these institutions academically. Only a university, not a college, can issue doctoral degrees in Israel.
== Biochemistry == In prokaryotes and eukaryotes, GGT consists of two polypeptide chains, a heavy and a light subunit, processed from a single chain precursor by an autocatalytic cleavage. The active site of GGT is known to be located in the light subunit. Co-translational N-glycosylation serves a significant role in the proper autocatalytic cleavage and proper folding of GGT. Single site mutations at asparagine residues were shown to result in a functionally active yet slightly less thermally stable version of the enzyme in vitro, while knockout of all asparagine residues resulted in an accumulation of the uncleaved, propeptide form of the enzyme.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.